HMGB1 and Sepsis: Pharmacological inhibition of HMGB1 with neutralizing antibodies conferred protection against lethal sepsis, even when administered 24 hours post-CLP (24, 25), establishing HMGB1 as a “late” mediator of sepsis with a broader therapeutic window (26–30).